Mumbai, Dec. 28: Zydus Cadila, the Ahmedabad-based pharmaceutical company, today said it has acquired six brands from global drug major MSD and its subsidiaries for an undisclosed amount.

According to a Zydus Cadila statement, its wholly owned subsidiary Zydus Healthcare had acquired the brands, which cover various therapeutic areas, including wound management, from MSD and its subsidiaries.

MSD India is an affiliate of Merck & Co Inc that operates in over 140 countries.

The brands acquired are Deca-Durabolin, Durabolin, Sustanon, Multiload, Sicastat and Axeten.

The acquired portfolio had clocked sales worth Rs 84 crore in 2015. The deal includes the transfer of distribution and commercialisation rights and assignment of trademarks of all the six brands to Zydus Healthcare in India.

Zydus Cadila said the acquisition of the strategic brands would strengthen its portfolio in key therapeutic segments.

Multiload, an IUD (intrauterine device), is expected to widen the offerings in women's contraceptives, while Axeten is an anti-hypertensive brand. Sicastat is used for wound management.

"The brands with their strong equity are a perfect addition and complement our core business and brands. We look at this as a great opportunity to strengthen our core offerings to create value and growth," Zydus Healthcare chairman Sharvil Patel said.